The association between vascular endothelial growth factor expression in invasive breast cancer and survival varies with intrinsic subtypes and use of adjuvant systemic therapy: results from the Nurses’ Health Study

Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort study

(2010) Shaheenah Dawood et al.   BREAST CANCER RESEARCH AND TREATMENT

Epidermal growth factor receptor and vascular endothelial growth factor receptor 2 are specific biomarkers in triple-negative breast cancer. Results from a controlled randomized trial with long-term follow-up

(2010) Lisa Rydén et al.   BREAST CANCER RESEARCH AND TREATMENT

Aspirin Intake and Survival After Breast Cancer

(2010) Michelle D. Holmes et al.   JOURNAL OF CLINICAL ONCOLOGY

Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies

(2010) Fiona M. Blows et al.   PLOS MEDICINE

The role of VEGF in triple-negative breast cancer: where do we go from here?

(2009) S. F. Dent   ANNALS OF ONCOLOGY

Significantly higher levels of vascular endothelial growth factor (VEGF) and shorter survival times for patients with primary operable triple-negative breast cancer

(2009) B. K. Linderholm et al.   ANNALS OF ONCOLOGY

Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor

(2009) B. Linderholm et al.   MEDICAL ONCOLOGY

Estrogen receptor-β expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study

(2009) Jonathan D Marotti et al.   MODERN PATHOLOGY

Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts

(2009) C. L. Roland et al.   MOLECULAR CANCER THERAPEUTICS

Enhancement of vascular endothelial growth factor-mediated angiogenesis in tamoxifen-resistant breast cancer cells: role of Pin1 overexpression

(2009) M. R. Kim et al.   MOLECULAR CANCER THERAPEUTICS

Vascular endothelial growth factor is a strong predictor of early distant recurrences in a prospective study of premenopausal women with lymph-node negative breast cancer

(2008) Barbro K. Linderholm et al.   BREAST

Vascular Endothelial Growth Factor Reduces Tamoxifen Efficacy and Promotes Metastatic Colonization and Desmoplasia in Breast Tumors

(2008) Z. Qu et al.   CANCER RESEARCH

Prognostic Effect of Basal-Like Breast Cancers Is Time Dependent: Evidence from Tissue Microarray Studies on a Lymph Node-Negative Cohort

(2008) A. M. Mulligan et al.   CLINICAL CANCER RESEARCH

Basal-Like Breast Cancer Defined by Five Biomarkers Has Superior Prognostic Value than Triple-Negative Phenotype

(2008) M. C.U. Cheang et al.   CLINICAL CANCER RESEARCH

High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer

(2008) Sriparna Ghosh et al.   HUMAN PATHOLOGY